Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06319456 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 6 → 10 locations Study title shortened, about 1 wordv5 Show 1 more changeShow less
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 5 to 6v4
  3. Start date changed from estimate of Apr 2024 to Apr 7, 2024v3
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 2 to 5v2 Show 1 more changeShow less
    • Study sites: 2 to 5
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
Trial Details
NCT Number NCT06319456
Lead Sponsor Ascentage Pharma Group Inc.
Conditions CLL/SLL
Enrollment 344 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov